Bio 2015 Customer Showcase
Flowmetric Diagnostics discusses HPC-150 portable flow cytometer within FlowMetric Diagnostics’ mobile point-of-care diagnostic laboratory, the MoPod™. This unprecedented model of mobile laboratory platform was presented at the BIO International Conference at Philadelphia (June 15 - 18, 2015). By virtue of this strategic collaboration, both handyem and FlowMetric Diagnostics intend to accelerate flow cytometry as a precise and low cost diagnostic platform to service North American and Global medical needs.
Flowmetric Diagnostics discusses HPC-150 portable flow cytometer within FlowMetric Diagnostics’ mobile point-of-care diagnostic laboratory, the MoPod™. This unprecedented model of mobile laboratory platform was presented at the BIO International Conference at Philadelphia (June 15 - 18, 2015). By virtue of this strategic collaboration, both handyem and FlowMetric Diagnostics intend to accelerate flow cytometry as a precise and low cost diagnostic platform to service North American and Global medical needs.
ICON discusses with PharmTech the advancement of research and development in 2015.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
